Terms: = Prostate cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Treatment
49 results:
1. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
2. treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
3. The ELAVL3/mycn positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y; Zhang W; Shen K; Su R; Liu X; Ma Z; Liu B; Hu C; Xue Y; Xin Z; Yang Y; Li A; Jiang Z; Jing N; Zhu HH; Dong L; Zhu Y; Dong B; Pan J; Wang Q; Xue W
Nat Commun; 2023 Nov; 14(1):7794. PubMed ID: 38016952
[TBL] [Abstract] [Full Text] [Related]
4. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract] [Full Text] [Related]
5. Neurokinin-1 receptor drives PKCɑ-AURKA/n-myc signaling to facilitate the neuroendocrine progression of prostate cancer.
Zhang XW; Li JY; Li L; Hu WQ; Tao Y; Gao WY; Ye ZN; Jia HY; Wang JN; Miao XK; Yang WL; Wang R; Mou LY
Cell Death Dis; 2023 Jun; 14(6):384. PubMed ID: 37385990
[TBL] [Abstract] [Full Text] [Related]
6. CHRM4/AKT/mycn upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract] [Full Text] [Related]
7. Targeting PKLR/mycn/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy.
Sandhu HS; Portman KL; Zhou X; Zhao J; Rialdi A; Sfakianos JP; Guccione E; Kyprianou N; Zhang B; Mulholland DJ
Cell Rep; 2022 Jul; 40(4):111123. PubMed ID: 35905714
[TBL] [Abstract] [Full Text] [Related]
9. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for n-myc Overexpressing Neuroendocrine prostate cancers.
Elhasasna H; Khan R; Bhanumathy KK; Vizeacoumar FS; Walke P; Bautista M; Dahiya DK; Maranda V; Patel H; Balagopal A; Alli N; Krishnan A; Freywald A; Vizeacoumar FJ
Cells; 2022 Jul; 11(14):. PubMed ID: 35883689
[TBL] [Abstract] [Full Text] [Related]
10. n-myc promotes angiogenesis and therapeutic resistance of prostate cancer by TEM8.
Li M; Fang L; Kwantwi LB; He G; Luo W; Yang L; Huang Y; Yin S; Cai Y; Ma W; Zhan H; Tong Z; Zhang L; Liang C; Yin Y
Med Oncol; 2021 Sep; 38(10):127. PubMed ID: 34523032
[TBL] [Abstract] [Full Text] [Related]
11. The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
Quan Y; Zhang X; Butler W; Du Z; Wang M; Liu Y; Ping H
Int J Biol Sci; 2021; 17(13):3288-3304. PubMed ID: 34512147
[TBL] [Abstract] [Full Text] [Related]
12. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
[TBL] [Abstract] [Full Text] [Related]
13. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant prostate cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract] [Full Text] [Related]
14. A modern era of personalized medicine in the diagnosis, prognosis, and treatment of prostate cancer.
Lakshmanan VK; Ojha S; Jung YD
Comput Biol Med; 2020 Nov; 126():104020. PubMed ID: 33039808
[TBL] [Abstract] [Full Text] [Related]
15. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract] [Full Text] [Related]
16. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
17. Combination of NDRG2 overexpression, X-ray radiation and docetaxel enhances apoptosis and inhibits invasiveness properties of LNCaP cells.
Alizadeh Zarei M; Rafiei Dehbidi G; Takhshid MA
Urol Oncol; 2020 Nov; 38(11):849.e1-849.e9. PubMed ID: 32665121
[TBL] [Abstract] [Full Text] [Related]
18. PARP Inhibition Suppresses GR-mycn-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant prostate cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract] [Full Text] [Related]
19. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
Huang YH; Zhang YQ; Huang JT
Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
[TBL] [Abstract] [Full Text] [Related]
20. n-myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract] [Full Text] [Related]
[Next]
